A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

NCT07540338 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Bipolar I Disorder

Interventions

DRUG: AL001
DRUG: Lithium carbonate

Sponsor

Alzamend Neuro, Inc.

Collaborators

[object Object]